The lawsuit, filed by the Rosen Law Firm, claims Zoetis management issued false or misleading statements regarding the company's market share and sales growth. According to the complaint, the firm failed to disclose that demand for Librela, a canine pain treatment, weakened significantly following FDA safety warnings about neurological complications. Additionally, the suit alleges that the company's Simparica Trio and dermatology products, Apoquel and Cytopoint, were losing ground to lower-priced competitors in a cooling market.
In section Releases
Zoetis Investors Face July Deadline in Securities Fraud Litigation
Investors who purchased Zoetis Inc. securities between January 14, 2025, and May 6, 2026, have until July 27 to move the court to serve as lead plaintiff in an ongoing class action lawsuit alleging the company misled shareholders about the performance and safety of its key veterinary products.
Investors are not required to take immediate action to remain part of the potential class, but those wishing to act as a lead plaintiff must file a motion by the July 27 deadline. While a class has not yet been certified, affected shareholders may retain their own counsel or choose to participate as absent members. The litigation aims to recover damages for investors who experienced losses when the alleged details regarding the company's declining competitive position entered the market.
Comments (0)
No comments yet. Be the first!